| New support for the big sort hypothesis: an assessment of partisan geographic sorting in California, 1992–2010 J Sussell PS: Political Science & Politics 46 (4), 768-773, 2013 | 75 | 2013 |
| Understanding pregnancy‐related attitudes and behaviors: A mixed‐methods study of homeless youth JS Tucker, J Sussell, D Golinelli, A Zhou, DP Kennedy, SL Wenzel Perspectives on sexual and reproductive health 44 (4), 252-261, 2012 | 50 | 2012 |
| Nurse practitioners and sexual and reproductive health services: An analysis of supply and demand DI Auerbach, ML Pearson, D Taylor, M Battistelli, J Sussell, LE Hunter, ... Rand Health Quarterly 2 (3), 2012 | 36* | 2012 |
| The economic burden of kidney graft failure in the United States J Sussell, AR Silverstein, P Goutam, D Incerti, R Kee, CX Chen, ... American Journal of Transplantation 20 (5), 1323-1333, 2020 | 23 | 2020 |
| Are changing constituencies driving rising polarization in the US House of Representatives? J Sussell, JA Thomson Rand Corporation, 2015 | 21 | 2015 |
| Evaluation of the re-integration of ex-offenders (RExO) program: Two-year impact report A Wiegand, J Sussell, E Valentine, B Henderson US Department of Labor, Employment and Training Administration, 2015 | 15 | 2015 |
| Cost-effectiveness analysis of ado-trastuzumab emtansine (T-DM1) for the adjuvant treatment of patients with residual invasive HER2+ early breast cancer in the United States J Sussell, GS Jhuti, V Antao, O Herrera-Restrepo, E Wehler, SP Bilir American Journal of Clinical Oncology 44 (7), 340-349, 2021 | 13 | 2021 |
| Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant … J O’Shaughnessy, N Robert, S Annavarapu, J Zhou, J Sussell, A Cheng, ... Breast Cancer Research and Treatment 187, 903-913, 2021 | 13 | 2021 |
| HER2-positive metastatic breast cancer: a retrospective cohort study of healthcare costs in the targeted-therapy age JA Sussell, D Sheinson, N Wu, B Shah-Manek, A Seetasith Advances in Therapy 37, 1632-1645, 2020 | 12 | 2020 |
| How much of the cocaine market are we missing? Insights from respondent-driven sampling in a mid-sized American city JP Caulkins, J Sussell, B Kilmer, A Kasunic Drug and alcohol dependence 147, 190-195, 2015 | 12 | 2015 |
| Challenges with forecasting budget impact: a case study of six ICER reports JT Snider, J Sussell, MG Tebeka, A Gonzalez, JT Cohen, P Neumann Value in Health 22 (3), 332-339, 2019 | 11 | 2019 |
| Using respondent-driven sampling to recruit illegal drug purchasers to evaluate a drug market intervention AJ Ober, J Sussell, B Kilmer, J Saunders, DD Heckathorn Evaluation review 40 (2), 87-121, 2016 | 9 | 2016 |
| Evaluation of the Re-Integration of Ex-Offenders (RExO) Program: Final Impact Report.” A Wiegand, J Sussell Washington, DC: US Department of Labor, 2016 | 9 | 2016 |
| Reconsidering the economic value of multiple sclerosis therapies Y Liu, JJ Shim, D Lakdawalla The American Journal of Managed Care 22 (11), e368-e374, 2016 | 9 | 2016 |
| Does San Francisco's Community Justice Center Reduce Criminal Recidivism? B Kilmer, J Sussell Rand Corporation, 2014 | 9 | 2014 |
| Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment … F Manevy, G Filkauskas, P Levy, J Fredriksson, J Sussell Journal of Clinical Oncology 39 (15_suppl), 544-544, 2021 | 8 | 2021 |
| Associations between geography, decision‐making style, and interest in cancer clinical trial participation NE Caston, CP Williams, C Wan, S Ye, C Pywell, SA Ingram, A Azuero, ... Cancer 128 (22), 3977-3984, 2022 | 6 | 2022 |
| Risk factors and costs associated with 30-day readmissions following alcohol-related hospitalizations in the United States from 2010 to 2015 AR Silverstein, R Kee, CD Gleeson, J Sussell, AK O'Sullivan, ... Alcohol 89, 19-25, 2020 | 5 | 2020 |
| Value-based payments and incentives to improve care: a case study of patients with type 2 diabetes in medicare advantage J Sussell, TT Schwartz, J Shafrin, JJ Sheehan, W Aubry, D Scanlon Value in Health 20 (8), 1216-1220, 2017 | 5 | 2017 |
| Assessment of the cost-effectiveness of HER2-targeted treatment pathways in the neoadjuvant treatment of high-risk HER2-positive early-stage breast cancer JA Sussell, JA Roth, CS Meyer, A Fung, SA Hansen Advances in Therapy 39 (3), 1375-1392, 2022 | 4 | 2022 |
Beau KilmerDirector, RAND Drug Policy Research CenterVerified email at rand.org
